(NP (NP (NNS Effects)) (PP (IN of) (NP (NNS glucocorticoids))) (PP (IN on) (NP (NN lymphocyte) (NN activation))) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (ADJP-COOD (ADJP (JJ steroid-sensitive)) (CC and) (ADJP (JJ steroid-resistant))) (NN asthma))))) (. .))
(S (NP (NN BACKGROUND) (: :)) (S (NP-SBJ (NNS Glucocorticoids)) (VP (VBP are) (NP-PRD (NP (JJ important) (NNS medications)) (VP (VBN used) (NP-103 (-NONE- *)) (S (NP-SBJ (-NONE- *-103)) (VP (TO to) (VP (VB control) (NP (NP (DT the) (NN airway) (NN inflammation)) (VP (VBN associated) (NP (-NONE- *)) (PP (IN with) (NP (NN asthma))))))))))) (. .)))
(S (NP-SBJ (JJ Synthetic) (NNS glucocorticoids)) (VP (VBP vary) (PP (IN in) (NP (NP (PRP$ their) (NN binding) (NN affinity)) (PP (IN for) (NP (NP (DT the) (NN glucocorticoid) (NN receptor)) (PRN (-LRB- -LRB-) (NP (NN GCR)) (-RRB- -RRB-))))))) (. .))
(S (NP (NNS METHODS) (: :)) (S (NP-SBJ (PRP We)) (VP (VBD compared) (NP (NP-COOD (NP (NN hydrocortisone)) (, ,) (NP (NN beclomethasone) (NN dipropionate)) (, ,) (NP (NN triamcinolone) (NN acetonide)) (, ,) (NP (NN flunisolide)) (, ,) (CC and) (NP (NN budesonide))) (PP (-NONE- *ICH*-104))) (PP (IN with) (NP (NP (NN regard)) (PP (TO to) (NP (PRP$ their) (NN capacity) (S (NP-SBJ (-NONE- *)) (VP (TO to) (VP (VB inhibit) (NP (JJ phytohemagglutinin-induced) (JJ peripheral) (NN blood) (JJ mononuclear) (NN cell) (NN proliferation))))))))) (PP-104 (IN from) (NP-COOD (NP (NP (CD six) (NNS patients)) (PP (IN with) (NP (JJ steroid-sensitive) (NN asthma)))) (CC and) (NP (NP (CD seven) (NNS patients)) (PP (IN with) (NP (JJ steroid-resistant) (NN asthma))))))) (. .)))
(S (NP-SBJ-36 (NP (JJ Peripheral) (NN blood) (JJ mononuclear) (NN cell) (NN GCR) (NN binding) (NNS affinities)) (PP (IN for) (NP-COOD (NP (NN dexamethasone)) (CC and) (NP (NN budesonide))))) (VP (VBD were) (VP (ADVP (RB also)) (VBN determined) (NP (-NONE- *-36)) (PP (IN for) (NP (DT both) (NN patient) (NNS groups))) (PP (IN by) (S (NP-SBJ (-NONE- *)) (VP (VBG using) (NP-COOD (NP (DT a) (NN radioligand) (NN binding) (NN assay)) (CC and) (NP (NN Scatchard) (NN analysis)))))))) (. .))
(S (NP (NNS RESULTS) (: :)) (S (NP-SBJ-37 (JJ Dose-dependent) (NN inhibition)) (VP (VBD was) (VP (VBN demonstrated) (NP (-NONE- *-37)) (PP (IN for) (NP (DT all) (NNS glucocorticoids))) (PP (IN in) (NP (DT both) (NN patient) (NNS groups))) (, ,) (PP (IN with) (S (NP-SBJ (DT the) (JJ steroid-resistant) (NN group)) (VP (VBG requiring) (NP (QP (RB approximately) (CD 2) (JJ log-fold) (JJR more)) (NNS glucocorticoids)) (PP (IN for) (NP (NP (DT an) (JJ equivalent) (NN degree)) (PP (IN of) (NP (NN inhibition)))))))))) (. .)))
(S-COOD (S (NP-SBJ (NP (DT The) (NN mean) (NNS concentrations)) (ADJP (JJ necessary) (S (NP-SBJ (-NONE- *)) (VP (TO to) (VP (VB cause) (NP (NP (NP (CD 50) (NN %) (NN inhibition)) (PP (IN of) (NP (NN lymphocyte) (NN proliferation)))) (PRN (-LRB- -LRB-) (NP (NNS IC50s)) (-RRB- -RRB-))) (PP (IN for) (NP (DT the) (JJ steroid-sensitive) (NN group)))))))) (VP (VBD ranged) (PP-COOD (PP (IN from) (NP (NP (QP (CD 2) (CC x) (CD 10-LRB--10-RRB-)) (NN (L mol))) (PP (IN for) (NP (NN budesonide))))) (PP (TO to) (NP (NP (QP (CD 7) (CC x) (CD 10-LRB--8-RRB-)) (NN (L mol))) (PP (IN for) (NP (NN hydrocortisone)))))))) (, ,) (IN whereas) (S (NP-SBJ (NP (DT the) (NN mean) (NNS IC50s)) (PP (IN for) (NP (DT the) (JJ steroid-resistant) (NN group)))) (VP (VBD ranged) (PP-COOD (PP (IN from) (NP (NP (QP (RB approximately) (CD 2) (CC x) (CD 10-LRB--8-RRB-)) (NN (L mol))) (PP (IN for) (NP (NN budesonide))))) (PP (TO to) (NP (NP (QP (JJR greater) (IN than) (CD 10-LRB--6-RRB-)) (NN (L mol))) (PP (IN for) (NP (NN hydrocortisone)))))))) (. .))
(S (PP (IN In) (NP (NN addition))) (, ,) (NP-SBJ-38 (DT a) (JJ significant) (NN correlation)) (VP (VBD was) (VP (VBN noted) (NP (-NONE- *-38)) (PP (IN between) (NP-COOD (NP (NP (DT the) (NN degree)) (PP (IN of) (NP (NP (NP (NN inhibition)) (PP (IN of) (NP (NN lymphocyte) (NN proliferation)))) (PRN (-LRB- -LRB-) (NP (NN IC50)) (-RRB- -RRB-))))) (CC and) (NP (NP (DT the) (NN binding) (NN affinity)) (PP (IN of) (NP (NN dexamethasone))) (PP (TO to) (NP (DT the) (NN GCR)))))))) (. .))
(S (NP-SBJ-39 (NP (NNS Patients)) (PP (IN with) (NP (JJ steroid-resistant) (NN asthma)))) (VP (VBP have) (VP (VBN been) (VP (VBN shown) (S (NP-SBJ (-NONE- *-39)) (VP (TO to) (VP (VB have) (NP (DT a) (VBN reduced) (NN GCR) (NN binding) (NN affinity)))))))) (. .))
(S (NP-SBJ (NP (DT The) (NN GCR) (NN binding) (NN affinity)) (PP (IN for) (NP (NN budesonide)))) (VP (VP (VBD was) (ADJP-PRD (ADJP (RB significantly) (JJR higher)) (PP (-NONE- *ICH*-105))) (PP (IN in) (NP (DT both) (NNS groups)))) (NP (-LRB- -LRB-) (ADVP (FW i.e.)) (, ,) (NP (JJR lower) (NN dissociation) (NN constant)) (-RRB- -RRB-)) (PP-105 (IN than) (NP (NP (DT that)) (VP (VBN obtained) (NP (-NONE- *)) (PP (IN for) (NP (NN dexamethasone))))))) (. .))
(S (NP (NN CONCLUSION) (: :)) (S (NP-SBJ (DT These) (NNS data)) (VP (VBP suggest) (SBAR (IN that) (S (NP-SBJ (NP (NNS glucocorticoids)) (PP (JJ such) (IN as) (NP (NN budesonide)))) (, ,) (PP (IN by) (NN virtue) (IN of) (NP (PRP$ their) (NP-COOD (NP (JJ high) (NN GCR) (NN binding) (NNS affinities)) (CC and) (NP (JJR greater) (NN ability) (S (NP-SBJ (-NONE- *)) (VP (TO to) (VP (VB suppress) (NP (NN lymphocyte) (NN proliferation))))))))) (, ,) (VP (MD may) (ADVP (RB therefore)) (VP (VB be) (ADJP-PRD (JJ beneficial)) (PP (IN in) (NP (NP (DT the) (NN management)) (PP (IN of) (NP (JJ difficult-to-control) (NN asthma)))))))))) (. .)))
